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overall survival in multivariate analysis. As to progression-
free survival, disease-free interval, PALN size, and upfront 
radiotherapy (or chemoradiotherapy) were significant 
prognostic factors in multivariate analysis. Acute grade 3 
gastrointestinal and hematologic toxicities developed in 3 
patients. 
 
Conclusion: For isolated PALN recurrence of cervical cancer, 
upfront radiotherapy (or chemoradiotherapy) should be 
considered as a salvage treatment, especially in patients with 
long disease-free interval. 
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Purpose or Objective: To present the long term outcomes 
and results of the clinical audit of cervical cancer cases 
treated at our cancer centre in the year 2010. 
 
Material and Methods: A clinical audit of case records of 
cervical cancer treated at our centre in the year 2010 was 
analysed. Out of the 306 patients evaluated for Cervical 
Cancer, case records for demographics, treatment 
methodology, long term toxicity and survival data was 
analysed using the SPSS. The variables were compared using 
the Chi-square test, the survival by Log-Rank test. 
 
Results: Out of a total of 306 patients with a median age 
group of 50 years (range-30-80) evaluated for various 
symptoms pertaining to cervical cancer, 204 underwent 
concurrent chemoradiation and 102 patients received only 
radiation alone. In the total cohort, FIGO stage grouping was 
stage II in 36% (n=111), stage III in 56% (n=172) and stage IVA 
in the remaining. Radiation was delivered to a dose of 75Gy 
to point A, external beam radiotherapy (dose of 45-50Gy) 
being delivered predominantly on the Telecobalt and 
followed with low dose rate brachytherapy. Cisplatin based 
concurrent chemotherapy was delivered as weekly at a dose 
of 40 mg/sqm in 76% of the patients, while in the rest it was 
delivered as three-weekly regimen. In the weekly 
chemotherapy arm, 70% of them received atleast 4 cycles. 
Median overall treatment time (OTT) was 8.4 weeks (40-95 
days). At a median follow up of 36 months, 5 year overall 
survival in the entire cohort was 30%. The OS in the 
concurrent chemo radiation arm was better (34% Vs. 29%, 
p=0.036). The OS in the two chemotherapy arms did not show 
a difference (log rank, p=0.46). The survival difference 
between the two stage groups demonstrated a superior 
outcome in patients with stage II (40% vs 32%, p=<0.05). 
Multivariate analysis showed stage, type of chemotherapy 
and overall treatment (OTT) time were significant for OS. 
Acute hematologic, GI, GU and skin toxicity was higher in 
chemoradiation arm. Difference in long term toxicity 
between the two treatment arms was not statistically 
significant. 
 
Conclusion: Our clinical audit of cervical cancer cases 
treated at our cancer centre, although demonstrates slight 
inferior survival outcome compared to available literature, 
might be accounted for the lower Point A dose, longer overall 
treatment time, and suboptimal chemotherapy dose. These 
factors have been taken care in our current clinical practice. 
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Purpose or Objective: Endometrial cancer (EC) is the most 
common gynecologic malignancy in developed countries, 
affecting 40,000 women/year. Recent studies have shown the 
therapeutic benefit of pelvic lymphnode dissection in order 
to determine the extent of desease and establish adiuvant 
therapies. Several trials have also shown that adiuvant 
radiotherapy(RT) in early stage EC reduces the risk of local 
recurrence without improving overall survival (OS). However 
the role of both lymphnode dissection and adiuvant RT in 
high risk early stage EC is not clearly defined. The aim of our 
retrospective study is to evaluate the validity of 
linfadenectomy with intravaginal brachiterapy (IVRT) as 
therapeutic option in high risk early stage EC, compare it 
with adjuvant external beam radiotherapy (EBRT) and 
determine which one determine the best results in terms of 
Reccurrence Free Survival (RFS) and OS. 
 
Material and Methods: Were evalueted 85 patients with EC 
treated between January 2007 and January 2012 with 36 
months of follow-up. Of these, 47 had low risk early stage 
(G1 with myometrial infiltration less than 50% or G2 with 
myometrial infiltration less than one third ) treated with 
bilateral histerosalpingovariectomy without any adjuvant 
therapy; 38 were patients with high risk early stage (G1 with 
more than 50% of myometrial invasion, G2 with more than 
one third of myometrial infltration and G3) treated with 
bilateral hysterosalpingo-oophorectomy and then submitted 
to pelvic lymphadenectomy (n. 22 pts) plus IVRT or EBRT (n. 
16 pts) based on age, comorbidities, tumor grade, histotype, 
tumor size, presence of lymphovascular invasion space, depth 
or myometrial infiltration. 
 
Results: The recurrence rate was respectively of 4% (n.2 pts) 
among the low risk patients with a RFS of 96% and of 19% 
(n.11 pts) among the high risk patients with a RFS of 81%. 
Considering the high risk group, the 45% of recurrence 
(n.5pts) occurred among patients treated with EBRT and the 
55%(n.6pts) among those who received lymphadenectomy 
with IVRT. The mortality rate was respectively 0% (n.0 pts) 
among patients treated with EBRT and 0% (n.0 pts) among 
those who received lymphadenectomy with IVRT. 
 
Conclusion: Our study shows that in high risk early stage EC 
there is no significant difference in terms of RFS among 
patients who received pelvic lymphadenectomy with IVRT 
and those which had been treated with EBRT. There was also 
no statistically significant difference for OS between the two 
groups. 
 
EP-1325  
Phase I/II study of weekly cisplatin plus paclitaxel and 
radiotherapy for primary cervical cancer 
L. Zhu
1Peking University Third Hosiptal, Radiation Oncology, 
Beijing, China 
1, W. Jiang1, S. Tian1, A. Qu1, H. Wang1, X. Li1, A. Liao1, 
Y. Jiang1, J. Wang1 
 
Purpose or Objective: To determine the maximum tolerated 
dose (MTD) and effectiveness of weekly PTX plus DDP 
concurrent with whole pelvic irradiation in Chinese women 
with locally advanced cervical cancer. 
 
Material and Methods: Between November 2008 and March 
2015, a total of 36 patients with primarycervical cancer 
cervical cancer, FIGO stage IB1 to IIIB, confirmed by 
histology, negative para-aortic lymph nodes were enrolled 
into this phase I / II trial. Chemotherapy agents were 
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administered in escalating doses to cohorts of three patients 
at each dose level. Phase II was then assessed at the selected 
maximum tolerated dose (MTD). The patients were monitored 
for acute toxicity using the Common Toxicity Criteria, version 
3.0 and late toxicity using the RTOG/EORTC.tween November 
2008 and March 2015, a total of 36 patients with primary 
carcinoma of the cervix, FIGO stage IB1 to IIIB, confirmed by 
histology, negative para-aortic lymph nodes were enrolled 
into this phase I / II trial. Chemotherapy agents were 
administered in escalating doses to cohorts of three patients 
at each dose level. Phase II was then assessed at the selected 
maximum tolerated dose (MTD). The patients were monitored 
for acute toxicity using the Common Toxicity Criteria, version 
3.0 and late toxicity using the RTOG/EORTC. 
 
Results: Of the 36 patients, 18 enrolled on phase I study. The 
MTD was confirmed to be paclitaxel 40mg/m2 and cisplatin 
40mg/m2 administered weekly for six cycles with 3D 
conformal external beam radiotherapy. There were 
additional 18 evaluable patients for the phase II 
analysis，yielding a total of 21 patients at the MTD. 3° (9/21) 
hematologic, principally neutropenia, occurs late cycles. All 
patients finished 5-6 cycles chemotherapy and radiotherapy 
in 7 weeks. The median follow-up was 24 months (5-58). At 4 
months, 18 CR (1 pCR), 3 PR. At 24 months local control rate 
was 90.4 %（19/21）. 18/21 patients (85.7％) are still survive 
( 1 was loss of follow-up). 2 of 2 recurrent or metastasis 
patients have died. Late toxicities did not appear during 
follow-up. 
 
Conclusion: Combination PTX and DDP administered 
concurrently with pelvic EBRT can be safely administered at 
the MTD of DDP 40 mg/m2 and PTX 40 mg/m2 weekly for six 
cycles in Chinese women. Primary result showed a good 
clinical outcome. We need continue follow-up. Further 
development to determine if the combination will help yield 
a survival benefit. 
 
EP-1326 
The role of PET CT in the IMRT of cervical cancer: the 
experience of the Institute of Candiolo 
G. Cattari
1FPO-IRCCS CANDIOLO, Radiotherapy, Torino, Italy 
1, S. Squintu1, E. Delmastro1, E. Garibaldi1, S. 
Bresciani2, P. Scapoli3, S. Cauda3, C. Bracco2, T. Varetto3, P. 
Gabriele1 
2FPO-IRCCS CANDIOLO, Medical Physics, Torino, Italy 
3FPO-IRCCS CANDIOLO, Nuclear Medicine, Torino, Italy 
 
Purpose or Objective: This paper evaluates the impact of of 
FDG CT-PET in the treatment of cervical cancer by 
volumetric radiation and chemotherapy. 
 
Material and Methods: From June 2010 to October 2015, 38 
patients (pts) with cervical cancer were treated by 
radiotherapy, 21 with curatively (4 recurrences) and 17 with 
postoperatively (5 with positive margins). The mean age was 
58 years (range 32-88). The histology was: squamous cell 
carcinoma (26 pts), adenocarcinoma (9 pts), adenosquamous 
carcinoma (3 pts). The grading was: G3 in 14 pts, G2 in 23 
pts, G1 in 1 pt. The FIGO stage was: IB1 in 7 pts, IB2 in 3 pts, 
IIA1 in 5 pts, IIA2 in 2 pts, IIB in 13 pts, IIIA in 2 pts, IIIB in 2 
pts, IIIB2 in 1 pt, IIIC2 in 1 pt and IVA in 2 pts. 24 pts received 
concurrent chemotherapy (CHT), 3 neoadjuvant CHT and 1 
neoadjuvant and concomitant CHT. 3 pts were treated with 
IMRT by LINAC, 34 pts with image-guided IMRT-SB-IGRT using 
Helical Tomotherapy; 1 patient received exclusive High Dose 
Rate (HDR) brachytherapy. Tumor doses were ranged from 54 
to 70.4 Gy in 30-32 fractions (fr); dose to the pelvis were 
from 50.4 to 54 Gy / 25-30 fr. In 5 pts was treated lumbar-
aortic chain (51 Gy/30 fr); 14 pts received a boost on PET 
positive lymph nodes with dose range from 54 to 66 Gy/30 
fr). 24 pts were treated with HDR boost with dose/fraction of 
6-15 Gy in 1-3 frs. 
 
Results: 37 pts received a PET-CT to staging and planning 
(Philips GEMINI TF), 33 of these had a PET-CT evaluation post 
RT. PET –CT changed the previous stage of disease in 6/37 
cases (16%). 33 pts received also Magnetic Resonance (MRI) to 
staging, of these 10 showed positive lymph-nodes, conversely 
PET CT showed positive nodes in 20 pts (20%). 26 pts 
underwent a PET CT after RT: 18 pts showed a complete 
response (CR), 7 a partial response (PR), 1 pt a local 
persistence of lesion and a distance progression disease (PD). 
The time from end of treatment to PET evaluation was 
variable from 1 to 15 months (mean 4.3 months). About 6 pts 
with PR, 3 showed CR at the following PET-CT (8,12 and 14 
months), 1 local stable disease (SD) and distance metastases 
and 2 showed local and distance PD.  
 
Conclusion: FDG-PET changed tumor stage in 6/37 cases 
(16%) allowing a dose escalation on lymph-nodes detected 
and finally showed to be a sensitive and reliable method in 
the evaluation of radio-chemotherapy treatment response. 
The optimal timing of execution remains to be defined by 
further studies. 
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Purpose or Objective: To evaluate the toxicity and outcome 
of dose escalated radiotherapy using a simultaneous 
integrated boost (SIB) technique in patients with locally 
advanced cervical cancer at primary diagnosis or at nodal 
recurrence. 
 
Material and Methods: Sixteen patients with FIGO Stage IB2-
IIIB N1 were treated with intensity modulated radiation 
therapy utilizing a SIB technique for gross disease in the para-
aortic and/or pelvic nodal regions (8/16) or for microscopic 
disease after laparoscopic pelvic and para-aortic 
lymphadenectomy (8/16). Women were treated to 50.4 Gy in 
1.8 Gy fractions to the tumor region and the pelvic and / or 
para-aortic lymph node areas, and a simultaneous boost with 
59.36 Gy in 2.12 Gy fractions to the boost region. The boost 
volum was defined as 18FDG-PET/CT positive lymph nodes. 
Pulse-dose-rate brachytherapy was performed in eleven of 
sixteen and concurrent chemotherapy consisted of weekly 
cisplatin 40 mg/m2 in twelve patients. Acute and late 
toxicity, local control in the treated volumes, distant 
metastases and disease-free survival were assessed. 
 
Results: With a median follow-up of 22 months (range 3 -40), 
rates of acute > grade 2 gastro-intestinal (GI), genitourinary 
(GU), and hematologic toxicities were 19%, 0%, and 30%, 
respectively.There were no grade 4 acute toxicities. One 
patient developed a small bowel obstruction requiring 
surgical intervention at 16 months. The 2-year actuarial rate 
of grade ≥3 GI toxicity was 6%. There were no grade 3 or 4 
late GU or hematologic toxicities. All patients achieved 
complete remission in areas treated with high doses with SIB. 
Two patients presented a local recurrence at 6 and 30 
months of follow-up. Three cases of sixteen (19%) relapsed in 
this area when you analyzed with 18FDG-PET/CT, that 
resulted positive, but not present disease in the pathologic 
anatomy of the salvage lymphadenectomy in two of them. On 
the other hand, two of sixteen patients (12.5%) presented 
systemic disease (lung metastases) at 27 and 35 months of 
follow-up, for each patient respectively. And one patient 
presented a second neoplasm in urinary tract ten months 
after the initial treatment of the cervix neoplasm. The 2-year 
actuarial disease-free survival was 62.5% but noting that only 
one patient presented recurrence in the area of the SIB 
(6.25%).  
